Skip to main content
SpringerLink
Log in

Myeloid Growth Factors in Cancer Treatment

  • Chapter
Combination Therapies 2

Abstract

Myeloid growth factors are increasingly used in cancer treatment. Strategies include giving these factors before chemotherapy, to increase sensitivity of cancer cells to cell-cycle specific anticancer drugs, after chemotherapy to accelerate hematopoietic recovery or giving these factors without chemotherapy, to force maturation of cancer cells or to modulate the host immune response to cancer. Here, we consider the conceptual bases of these approaches and whether they are effective in treating human cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Foon K.A. Biological Response Modifiers: the new immunotherapy. Cancer Res. 49: 1621–39 (1989)

    PubMed  CAS  Google Scholar 

  2. Editorial. Interleukin-2: sunrise for immunotherapy. Lancet 2: 308 (1989)

    Google Scholar 

  3. Sachs L. The molecular control of blood cell development. Science 238: 1374–9 (1987)

    Article  PubMed  CAS  Google Scholar 

  4. Nicola N.A. Hemopoietic cell growth factors and their receptors. Annu. Rev. Biochem. 58: 45–77 (1989)

    Article  PubMed  CAS  Google Scholar 

  5. Moore M.A.S. Clinical implications of positive and negative hemopoietic stem cell regulators. Blood 78: 1–19 (1991)

    PubMed  CAS  Google Scholar 

  6. Zsebo K.M., Williams D.A., Geissler E.N. et al. Stem cell factor is encoded at the S 1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63: 213–24 (1990)

    Article  PubMed  CAS  Google Scholar 

  7. Ikebuchi K., Wong G.G., Clark S.C., Ihle J.N., Hirai Y., Ogawa M. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hematopoietic precursors. Proc. Natl. Acad. Sci. USA 84: 9035–9 (1987)

    Article  PubMed  CAS  Google Scholar 

  8. Kishi K., Ihle J.N., Urdal D.L., Ogawa M. Murine B- cell stimulatory factor-1 (BSF-1)/interleukin-4 (IL-4) is a multi-CSF which acts directly on primitive hemopoietic precursors. J. Cell. Physiol. 139: 463–8 (1989)

    Article  PubMed  CAS  Google Scholar 

  9. Musashi M., Clark S.C., Sudo T., Urdal D.L., Ogawa M. Synergic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic precursors of mice. Blood 78: 1448–51 (1991)

    PubMed  CAS  Google Scholar 

  10. Gasson J.C. Molecular physiology of granulocyte macrophage colony stimulating factor. Blood 77: 1131–45 (1991)

    PubMed  CAS  Google Scholar 

  11. Avalos B.R., Gasson J.C., Hedvat C. et al. Human granulocyte colony stimulating factor: biological activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 75: 851–7 (1990)

    PubMed  CAS  Google Scholar 

  12. Faisal M., Cumberland W., Chamlin W., Fahey J.L. Effect of recombinant human granulocyte macrophage colony stimulating factor administration on the lymphocyte subset of patients with refractory aplastic anemia. Blood 76: 1580–5 (1990)

    PubMed  CAS  Google Scholar 

  13. Asano S., Okano A., Ozawa K. et al. In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets. Blood 75: 1602–5 (1990)

    PubMed  CAS  Google Scholar 

  14. Kushner B.H., Cheung N.K.V. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73: 1936–41 (1989)

    PubMed  CAS  Google Scholar 

  15. Wing E.J., Magge D.M., Whiteside T.L., Kaplan S.S., Shadduck R.K. Recombinant human granulocyte macrophage colony stimulating factor enhances monocyte cytotoxicity and secretion of TNFa and interferon in cancer patients. Blood 73: 643–6 (1989)

    PubMed  CAS  Google Scholar 

  16. Sampson L.L., Heuser J., Brown E.J. Cytokine regulation of complement receptor mediated ingestion by mouse peritoneal macrophages. M-CSF and IL-4 activate phagocytosis by a common mechanism requiring autostimulation by IFN beta. J. Immunol. 146: 1005–13 (1991)

    PubMed  CAS  Google Scholar 

  17. W.E. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 77: 1859–70 (1991)

    Google Scholar 

  18. Kishimoto T. The biology of interleukin-6. Blood 74: 1–10 (1989)

    PubMed  CAS  Google Scholar 

  19. Fabian I., Kletter Y., Stavin S. Therapeutic potential of recombinant granulocyte macrophage colony stimulating factor and interleukin-3 in murine B cell leukemia. Blood 72: 913–8 (1988)

    PubMed  CAS  Google Scholar 

  20. Tepper R.I., Pattengale P.K., Leder P. Murine interleukin-4 dysplays potent anti-tumor activity in vivo. Cell 57: 503–12 (1989)

    Article  PubMed  CAS  Google Scholar 

  21. Nakamura S., Kashimoto S., Kajikawa F., Nakata K. Combination effect of recombinant human interleukin 1 alpha with antitumor activity on syngeneic tumors in mice. Cancer Res. 51: 215–21 (1991)

    PubMed  CAS  Google Scholar 

  22. Lu L., Shen R.N., Lin Z.H., Aukerman S.L., Ralph P., Broxemeyer H.E. Antitumor effects of recombinant human macrophage colony stimulating factor, alone or in combination with local irradiation, in mice inoculated with Lewis lung carcinoma cells. Int. J. Cancer 47: 143–7 (1991)

    Article  PubMed  CAS  Google Scholar 

  23. Miyauchi J., Kelleher C.A., Yang Y.C. et al. The effect of three recombinant growth factors, IL-3, GMCSF and G-CSF on the blast cells of acute myeloblastic leukemia mantained in short term suspension culture. Blood 70: 657–63 (1987)

    PubMed  CAS  Google Scholar 

  24. Delwel R., Saleim M., Pelleus C., et al. Growth regulation of human myeloid leukemia: effect of five recombinant hematopoietic factors in a serum-free culture system. Blood 72: 1944–9 (1988)

    PubMed  CAS  Google Scholar 

  25. Brach M.A., Lowemberg B., Mantovani L., Schwulera U., Martelmann R., Herrmann F. Interleukin-6 (IL-6) is an intermediate in IL-1 induced proliferation of leukemic human megakaryoblast. Blood 76: 1972–9 (1990)

    Google Scholar 

  26. Miyauchi J., Clark S.C., Tsunematsu Y. et al. Interleukin-4 as a growth regulator of clonogenic cells in acute myelogenous leukemia in suspension culture. Leukemia 5: 108–15 (1991)

    PubMed  CAS  Google Scholar 

  27. Baldwin G.C., Gasson J.C., Kaufman S.E. et al. Non hematopoietic tumor cells express functional GM-CSF receptors. Blood 73: 1033–7 (1989)

    PubMed  CAS  Google Scholar 

  28. Joraschkewitz M., Depenbrock H., Freund M. et al. Effects of cytokines on in vitro colony formation of primary human tumor specimens. Eur. J. Cancer 26: 1070–4 (1990)

    Article  PubMed  CAS  Google Scholar 

  29. Vellenga E., Biesma B., Meyer C., Wagteveld L., Esselink M., de Vries E.G. E The effect of five hematopoietic growth factors on human small cell lung carcinoma cell lines: interleukin 3 enhances the proliferation in one of the eleven cell lines. Cancer Res. 51: 73–6 (1991)

    PubMed  CAS  Google Scholar 

  30. Tungekar M.F., Turtley H., Dunnill M.S., Gatter K.C., Ritter M.A. Harris A.L. Interleukin-4 receptor on human lung tumors and normal lung. Cancer Res. 51: 261–4 (1991)

    PubMed  CAS  Google Scholar 

  31. Lotem J., Sachs L. In vivo control of differentiation of myeloid leukemia by recombinant granulocyte-macrophage colony stimulating factor and interleukin-3. Blood 71: 375–82 (1988)

    PubMed  CAS  Google Scholar 

  32. Shabo Y., Lotem J., Rubinstein M. et al. The myeloid blood cell differentiation-inducing protein MGI2a is interleukin-6. Blood 72: 2070–3 (1988)

    PubMed  CAS  Google Scholar 

  33. Miyauchi J., Kelleher C.A., Wang C., Minkin S. Mc Culloch E.A. Growth factors influence the sensivity of leukemic cells to cytosine arabinoside in culture. Blood 73: 1272–8 (1989)

    PubMed  CAS  Google Scholar 

  34. Butturini A., Santucci M.A., Gale R.P., Perocco P., Tura S. GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: a model for leukemia chemotherapy. Leukemia Res. 14: 743–9 (1990)

    Article  CAS  Google Scholar 

  35. Brach M., Klein H., Platzer E., Martelsmann R., Herrmann F. Effect of interleukin-3 on cytosine arabinoside-mediated cytotoxicity of leukemia myeloblasts. Exp. Hematol. 15: 2305–10 (1990)

    Google Scholar 

  36. Aurer I., Ribas A., Gale R.P. What is the role of recombinant colony stimulating factors in bone marrow transplantation? Bone Marrow Transpl. 6: 79–87 (1990)

    CAS  Google Scholar 

  37. Groopman M.D., Molina J.M., Scadden D.T. Hematopoietic growth factors. N. Engl. J. Med. 321: 1449–59 (1989)

    Google Scholar 

  38. Steward W.P., Verweij J., Somers R. et al. High dose chemotherapy (CT) with two schedules of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in the treatment of advanced adult soft tissue sarcomas (STS). ASCO Proc. 10: 349 (1991)

    Google Scholar 

  39. Jost L.M., Pichert G., Stahel R.A. Plecebo controlled phase I-II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy. Ann. Oncol. 1: 439–42 (1990)

    PubMed  CAS  Google Scholar 

  40. de Vries E.G., Biesma B., Willemse P.H. et al. A double blind placebo controlled study with granulocyte macrophage colony stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res. 51: 116–22 (1991)

    PubMed  Google Scholar 

  41. Bregni M., Siena S., Ravagnani F., Bonadonna G., Gianni A.M. High-dosecyclophosphamide in patients with operable breast cancer: recombinant human GM- CSF amiliorates drug-induced leukopenia and thrombocytopenia. Haematologica 75 (suppl.1): 95–8 (1990)

    PubMed  Google Scholar 

  42. Steward W.P., Scarffe J.H., Dirix L.Y. et al. Granulocyte-macrophage colony stimulating factor (GMCSF) after high dose melphalan in patients with advanced colon cancer. Br. J. Cancer 61: 749–54 (1990)

    Article  PubMed  CAS  Google Scholar 

  43. Bronchud M.H., Howell A., Crowther D., Hopwood P., Souza L., Dexter T.M. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br. J. Cancer 60: 121–25 (1989)

    Article  PubMed  CAS  Google Scholar 

  44. Crawford J., Ozer H., Stoller R. et al. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N. Engl. J. Med. 325: 164–70 (1991)

    Article  PubMed  CAS  Google Scholar 

  45. Eguchi K., Sasaki S., Tamura T. et al. Dose escalation study of recombinant human granulocyte-colony stimulating factor (KRN8601) in patients with advanced malignancy. Cancer Res. 49: 5221–4 (1989)

    PubMed  CAS  Google Scholar 

  46. Neidhart J., Mangalik A., Kohler W. et al. Granulocyte colony stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow trans plantation. J. Clin. Oncol. 7: 1685–92 (1989)

    PubMed  CAS  Google Scholar 

  47. Ganser A., Lindemann A., Seipelt G. et al. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76: 666–76 (1990)

    PubMed  CAS  Google Scholar 

  48. Kurzrock R., Talpaz M., Estrov Z., Rosenblum M.G., Gutterman J.U. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J. Clin. Oncol. 9: 1241–50 (1991)

    PubMed  CAS  Google Scholar 

  49. Postmus P.E., Gietema J.A., Damsma O., Willemse P. H. B., de Vries E.G.E., Vellenga E. Phase I trial of RH-interleukin-3 s.c. in patients with relapse of small cell lung cancer treated with chemotherapy. Asco Proc. 10: 248 (1991)

    Google Scholar 

  50. Crown J., Jakubowski A., Kemeny N. et al. A phase I trial of recombinant human Interleukin-lb alone and in combination with myelosupressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 78: 1420–7 (1991)

    PubMed  CAS  Google Scholar 

  51. Powles R., Smith C., Milan S. et al. Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukemia: double blind, placebo controlled trial. Lancet 336: 1417–20 (1990)

    Article  PubMed  CAS  Google Scholar 

  52. Nemunaitis J., Buckner C.D., Appelbaum F.R. et al. Phase I/II trial of recombinant human granulocyte-macrophage colony stimulating factor following allogeneic bone marrow transplantation. Blood 77: 2065–71 (1991)

    PubMed  CAS  Google Scholar 

  53. Nemunaitis J., Rabinowe S.N., Singer J.W. et al. Recombinant granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N. Engl. J. Med. 324: 1773–8 (1991)

    Article  PubMed  CAS  Google Scholar 

  54. Lazarus H. M., Andersen J., Chen M. G. et al. Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin’s lymphoma: blood and bone marrow progenitor growth studies. A phasell Eastern Cooperative Oncology Group Study. Blood 78: 830–7 (1991)

    PubMed  CAS  Google Scholar 

  55. Ho A.D., Del Valle F., Haas R. et al. Sequential studies of the role of mitoxantrone, high-dose cytarabine and recombinant human granulocyte-macrophage colony stimulating factor in the treatment of refractory non Hodgkin’s lymphoma. Sem. Oncol. 17 (supp.10): 14–8 (1990)

    CAS  Google Scholar 

  56. Barlogie B., Jagannath S., Dixon D.O. et al. High-dose melphalan and granulocyte macrophage colony stimulating factor for refractory multiple myeloma. Blood 76: 677–80 (1990)

    PubMed  CAS  Google Scholar 

  57. Ohno R., Tomonaga M., Kobayashi T. et al. Effect of granulocyte colony stimulating factor after intensive induction chemotherapy in relapsed or refractory acute leukemia. N. Engl. J. Med. 323: 871–7 (1990)

    Article  PubMed  CAS  Google Scholar 

  58. Masaoka T., Shibata H., Ohno R. et al. Double blind test of human urinary macrophage colony stimulating factor for allogeneic and syngeneic bone marrow transplantation: effectiveness of treatment and 2 year follow up for relapsed leukemia. Br. J. Haematol. 76: 501–5 (1990)

    Article  PubMed  CAS  Google Scholar 

  59. Buechner T., Hiddemann W., Koenigsmann M. et al. Recombinant human granulocyte macrophage colony stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: 1190–7 (1991)

    Google Scholar 

  60. Estey E.H., Dixon D., Kantarjan H.M. et al.Treatment of poor prognosis, newly diagnosed acute myeloid leukemia with AraC and recombinant human granulocyte macrophage colony stimulating factor. Blood 75: 1766–9 (1990)

    PubMed  CAS  Google Scholar 

  61. Budd J.T., Thomassen M.J., Murthy S.V. et al. Phase I trial of recombinant monocyte macrophage colony stimulating factor in patients with refractory malignancy. AACR Proc. 32: 172 (1991)

    Google Scholar 

  62. Zamkoff K., Hudson J., Groves E. et al. A phase I trial of recombinant macrophage stimulating factor, human (rM-CSF),by rapid intravenous infusion in patients with refractory malignancy. ASCO Prow 10: 93 (1991)

    Google Scholar 

  63. Tewari A., Buhles W.C., Starnes H.F. Preliminary report: effects of interleukin-1 on platelet count. Lancet 336: 712–4 (1990)

    Article  PubMed  CAS  Google Scholar 

  64. Steis R., Smith J., Janik J. Phase I study of recombinant interleukin-1b (Sintax). Asco Proc. 10: 211 (1991)

    Google Scholar 

  65. Davis I., Maher D., Cebon J. et al. Pharmacokinetic and clinical studies of interleukin-4 (IL-4) in patients with malignancy. ASCO Proc. 10: 287 (1991)

    Google Scholar 

  66. Freimann J., Estrov Z., Itoh H. et al. Phase I study of recombinant human interleukin-4. ASCO Proc. 10: 216 (1991)

    Google Scholar 

  67. Lotze M.T. Presented at the UCLA Symposium on Cellular Immunity and the Immunotherapy of Cancer. Park City (Utah). Jen. Feb. 1990

    Google Scholar 

  68. Thompson J.A., Lee D.J., Kidd P., Rubin E., Kaufmann J., Bonnem E.M., Fefer A. Subcutaneous granulocyte macrophage colony stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J. Clin. Oncol. 7: 629–37 (1989)

    PubMed  CAS  Google Scholar 

  69. Antin J.H., Weinberg D.S., Rosenthal D.S. Variable effect of recombinant human granulocyte macrophage colony stimulating factor on bone marrow fibrosis in patients with myelodysplasia. Exp. Hematol. 18: 266–70 (1990)

    PubMed  CAS  Google Scholar 

  70. Estey E.H., Kurzrock R., Talpaz M., et al. Effect of low doses of human granulocyte macrophage colony stimulating factor in patients with myelodysplastic syndrome. Br. J. Hematol. 77: 291–5 (1991)

    Article  CAS  Google Scholar 

  71. Negrin R.S., Haeuber D.H., Nagler A. et al. Maintanance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor. Blood 76: 36–43 (1990)

    PubMed  CAS  Google Scholar 

  72. Ganser A., Seipelt G., Lindemann A. et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76: 455–62 (1990)

    PubMed  CAS  Google Scholar 

  73. Bettelheim P., Valent P., Andreeff M. et al. Recombinant human granulocyte macrophage colony stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77: 700–11 (1991)

    PubMed  CAS  Google Scholar 

  74. Cannistra S.A., DiCarlo J., Groshek P., et al. Simultaneous administration of granulocyte macrophage colony stimulating factor and cytosine arabinoside for treatment of relapsed acute myeloid leukemia. Leukemia 5: 230–8 (1991)

    PubMed  CAS  Google Scholar 

  75. Buchner T., Hiddemann W., Wormann B et al. Multiple corse chemotherapy and GM-CSF from day minus one until neutrophil recovery versus chemotherapy alone in newly diagnosed AML. Ann. Hematol. 64 (suppl.1): A78 (1992)

    Google Scholar 

  76. Donatini B., Krupp P., Jones T. Ecogramostatim and pre-existing autoimmune thyroid disease. Lancet 338: 1526–7 (1991)

    Article  PubMed  CAS  Google Scholar 

  77. Canellos G.P. The case for high-dose chemotherapy: it is chemotherapy’s last gamble? Eur. J. Cancer Clin. Oncol. 4: 351–5 (1987)

    Article  Google Scholar 

  78. Dicke K.A., Armitage J.O., Dicke-Evinger B. “Autologous Bone Marrow Transplant V”. University of Nebraska Press. Omaha (1990)

    Google Scholar 

  79. Armitage J.O., Antman K.M. High-dose Cancer Therapy: Pharmacology, Hemopoietins And Stem Cells. William and Wilkins. New York (1991)

    Google Scholar 

  80. Korbling M., Holle R., Haas R. et al. Autologous blood stem cell transplantation in patients with advanced Hodgkin’s disease and prior radiation to the pelvic site. J. Clin. Oncol. 8: 978–85 (1990)

    PubMed  CAS  Google Scholar 

  81. Gianni A.M., Siena S., Bregni M. et al. Granulocyte-macrophage colony stimulating factor to harvest circulating hematopoietic stem cells for autotransplantation. Lancet 2: 580–4 (1988)

    Google Scholar 

  82. Lawler M., Humphries P., McCann S.R. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction. Blood 77: 2504–14 (1991)

    PubMed  CAS  Google Scholar 

  83. Laporte J.P., Fonillard L., Donay L. et al. GM-CSF instead of autologous bone marrow transplantation after the BEAM regimen. Lancet 338: 601–2 (1991)

    Article  PubMed  CAS  Google Scholar 

  84. Klasa R.J., Murray N., Coldman A.J. Dose-intensity meta-analysis of chemotherapy regimens in small cell carcinoma of the lung. J. Clin. Oncol. 9: 499–508 (1991)

    PubMed  CAS  Google Scholar 

  85. Meyer R.M., Hryniuk W.M., Goodyear M.D. The role of dose-intensity in determining outcome in intermediate grade non-Hodgkin lymphoma. J. Clin. Oncol. 9: 339–47 (1991)

    PubMed  CAS  Google Scholar 

  86. Dodwell D.J, Gurney H., Thatcher N. Dose intensity in cancer chemotherapy. Br. J. Cancer 61: 789–94 (1990)

    Article  PubMed  CAS  Google Scholar 

  87. Vadhan-Raj S., Broxmeyer H.E., Spitzer G. et al. Stimulation of non-clonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood 74: 1491–8 (1989)

    PubMed  CAS  Google Scholar 

  88. Told H., Matsutomo S., Okabe K., Shimokawa T. Remission in hypoplastic acute myeloid leukemia induced by granulocyte colony stimulating factor. Lancet 1: 1389–90 (1989)

    Google Scholar 

  89. Steward W.P., Scarffe J.H., Austin K. et al. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) given as daily short infusion in a phase I dose-toxicity study. Br. J. Cancer 59: 142–5 (1989)

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Parma, 43100, Italy

    Anna Butturini

  2. Department of Medicine, UCLA School of Medicine, Los Angeles, CA, 90024-1678, USA

    Robert Peter Gale

Authors
  1. Anna Butturini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Peter Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Rome “Tor Vergata”, Rome, Italy

    Enrico Garaci

  2. The Institute for Advanced Studies in Immunology and Aging, Washington, D.C., USA

    Allan L. Goldstein

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Butturini, A., Gale, R.P. (1993). Myeloid Growth Factors in Cancer Treatment. In: Garaci, E., Goldstein, A.L. (eds) Combination Therapies 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2964-4_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2964-4_21

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6289-0

  • Online ISBN: 978-1-4615-2964-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation